FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion

 

• RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema
• Approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept
• Vabysmo also demonstrated rapid and robust drying of retinal fluid
• Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other broadly used intravitreal treatments

https://www.biospace.com/article/releases/fda-approves-genentech-s-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo-/